Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alliance Pharma ( (GB:APH) ) has shared an announcement.
Alliance Pharma PLC has announced the approval of its acquisition by Aegros Bidco Limited, a company indirectly owned by DBAY Affiliates and the ERES IV Fund. The acquisition, which will be implemented through a Court-sanctioned scheme of arrangement, received overwhelming support from shareholders at both the Court Meeting and General Meeting. The acquisition is expected to enhance Alliance Pharma’s market position and operational capabilities, with the scheme anticipated to become effective in the first half of 2025.
More about Alliance Pharma
Alliance Pharma PLC operates in the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products. The company is known for its diverse portfolio of healthcare products, catering to various market needs.
YTD Price Performance: 39.89%
Average Trading Volume: 5,984,186
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £345.4M
For a thorough assessment of APH stock, go to TipRanks’ Stock Analysis page.